First Tracks Biotherapeutics, Inc. 8-K

What Happened
First Tracks Biotherapeutics, Inc. (TRAX) filed an 8‑K on April 20, 2026 confirming the completion of its spin‑off from AnaptysBio. The companies entered into a Separation and Distribution Agreement and a Transition Services Agreement governing asset and liability allocations, licensing, transition services (up to two years) and post‑spin operational matters. On the Distribution Date First Tracks issued 29,100,802 shares to AnaptysBio in connection with the transfer of its biopharma business assets. First Tracks also adopted its charter and bylaws, and appointed Ajim Tamboli as Chief Financial Officer effective April 20, 2026.

Key Details

• Spin‑Off closing date / 8‑K filing: April 20, 2026.
• Shares issued: 29,100,802 shares issued to AnaptysBio; AnaptysBio thereafter held 29,100,902 shares.
• Cash and assets allocated to First Tracks: $100.0 million in cash and cash equivalents plus intellectual property, programs (rosnilimab, ANB033, ANB101), lab equipment, IT and related assets. First Tracks may also receive up to $35.0 million in future Vanda‑related milestones.
• Transition Services Agreement: First Tracks will provide digital, HR, supply chain, finance, real estate and other services to AnaptysBio for up to two years (parties can shorten or terminate services by agreement).
• Registration Rights: First Tracks must file an SEC registration statement for resale of private placement shares by investors no later than 45 days after the Distribution Date.
• CFO appointment and compensation: Ajim Tamboli named CFO effective April 20, 2026; initial base salary $516,000, target annual cash bonus up to 40%, and equity grants valued at $2,550,000 with standard vesting; severance and change‑in‑control provisions included.
• Non‑employee director pay program established (cash retainers and equity: initial option for 14,000 shares + 5,000 RSUs; annual grants of 7,000 options + 2,500 RSUs).

Why It Matters
This 8‑K formalizes the split of AnaptysBio into two stand‑alone businesses: First Tracks (development-stage biopharma programs and operations) and a Royalty Management entity (holding certain royalties and related assets). Investors should note the material asset and cash allocation ($100M), the potential milestone upside from the Vanda collaboration (up to $35M), the required SEC registration for resale of private placement shares, and leadership continuity with a newly appointed CFO. The Transition Services Agreement and detailed indemnities/asset allocations will shape how smoothly First Tracks operates independently and how quickly it can stand up its own systems and contracts.